Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

Biogen Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Current portion of notes payable 0.00 3.99 4.23 4.18 4.20 0.00 0.00 0.00 0.00 0.00 5.75 5.49 5.44 0.00 0.00 0.00 0.00 0.00 0.01 0.01 2.48 2.57 2.65
Taxes payable 0.95 1.14 1.34 0.73 0.98 0.94 0.60 0.58 0.48 2.26 1.19 0.26 0.46 1.63 0.90 0.25 1.00 0.93 0.89 0.29 0.53 0.24 0.33
Accounts payable 1.54 1.73 1.69 2.47 1.80 1.53 1.80 1.85 1.60 1.50 1.49 1.95 1.39 1.43 1.43 1.47 1.34 1.23 1.33 1.67 1.29 1.52 1.49
Liabilities held for sale 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accrued expense and other 13.30 13.15 9.45 10.62 10.71 11.20 10.87 12.78 13.18 9.75 9.33 10.16 8.84 8.82 9.21 11.31 10.11 11.00 9.85 12.27 10.64 11.20 9.65
Current liabilities 15.80% 20.01% 16.71% 18.00% 17.69% 13.68% 13.27% 15.20% 15.26% 13.51% 17.76% 17.86% 16.13% 12.21% 11.91% 13.03% 12.45% 13.16% 12.08% 14.24% 14.95% 15.53% 14.12%
Notes payable, excluding current portion 25.26 25.03 26.58 26.28 26.35 29.71 30.46 30.16 29.78 29.10 17.08 16.37 16.22 22.63 22.47 23.47 23.27 24.75 22.73 25.09 25.74 27.36 28.08
Deferred tax liability 1.32 1.92 2.42 2.91 3.25 3.76 4.05 4.20 4.51 5.73 10.42 10.32 10.26 9.13 6.59 6.47 4.37 4.85 5.10 0.52 0.52 0.46 0.45
Long-term operating lease liabilities 1.43 1.09 1.32 1.38 1.46 1.49 1.59 1.63 1.64 1.63 1.55 1.52 1.49 1.61 1.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other long-term liabilities 4.82 4.66 5.45 5.53 5.54 5.54 5.92 5.40 5.73 5.78 5.20 4.95 4.99 5.16 5.12 5.49 5.93 6.09 6.29 6.89 3.11 3.45 3.25
Long-term liabilities 32.84% 32.69% 35.77% 36.10% 36.60% 40.49% 42.03% 41.39% 41.65% 42.24% 34.24% 33.16% 32.96% 38.53% 35.83% 35.44% 33.57% 35.68% 34.11% 32.50% 29.37% 31.28% 31.78%
Total liabilities 48.63% 52.70% 52.48% 54.10% 54.29% 54.17% 55.30% 56.59% 56.91% 55.75% 52.00% 51.02% 49.09% 50.74% 47.73% 48.47% 46.02% 48.84% 46.20% 46.74% 44.31% 46.81% 45.90%
Preferred stock, par value $0.001 per share 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, par value $0.0005 per share 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Additional paid-in capital 0.00 0.00 0.50 0.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.00 0.00 0.41 0.26 0.09 0.00
Accumulated other comprehensive loss -0.66 -0.44 -0.49 -0.45 -0.57 -0.70 -0.73 -1.21 -0.90 -0.71 -0.57 -0.50 -0.34 -0.96 -0.83 -0.95 -0.97 -1.09 -1.16 -1.35 -1.43 -1.56 -1.53
Retained earnings 64.04 59.65 60.20 58.26 56.89 56.81 57.99 56.77 55.99 56.71 60.01 60.42 62.09 61.56 64.38 64.29 66.47 64.71 66.44 66.84 69.81 68.39 69.74
Treasury stock, at cost -11.98 -11.87 -12.61 -12.47 -12.51 -12.17 -12.48 -12.09 -11.94 -11.67 -11.40 -10.93 -10.83 -11.33 -11.26 -11.77 -11.68 -12.43 -11.41 -12.59 -12.90 -13.68 -14.05
Total Biogen Inc. shareholders’ equity 51.40% 47.34% 47.61% 45.63% 43.81% 43.94% 44.78% 43.46% 43.15% 44.33% 48.04% 48.99% 50.92% 49.27% 52.30% 51.56% 54.00% 51.19% 53.87% 53.33% 55.74% 53.24% 54.16%
Noncontrolling interests -0.04 -0.04 -0.09 0.27 1.90 1.89 -0.08 -0.06 -0.06 -0.08 -0.04 -0.02 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.06 -0.06 -0.05 -0.05 -0.05
Total equity 51.37% 47.30% 47.52% 45.90% 45.71% 45.83% 44.70% 43.41% 43.09% 44.25% 48.00% 48.98% 50.91% 49.26% 52.27% 51.53% 53.98% 51.16% 53.80% 53.26% 55.69% 53.19% 54.10%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Biogen Inc. current liabilities as a percentage of total liabilities and equity increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Biogen Inc. long-term liabilities as a percentage of total liabilities and equity decreased from Q1 2022 to Q2 2022 but then slightly increased from Q2 2022 to Q3 2022.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Biogen Inc. total liabilities as a percentage of total liabilities and equity increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Total Biogen Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Biogen Inc. total Biogen Inc. shareholders’ equity as a percentage of total liabilities and equity decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 exceeding Q1 2022 level.